Ensign Peak Advisors’s Biogen BIIB Stock Holding History

Ensign Peak Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.07M	Buy	37,354 +3,644	+11%	+$697K	0.01%	476
2026 Q1	$6.18M	Buy	33,710 +23,034	+216%	+$4.24M	0.01%	494
2025 Q4	$1.88M	Sell	10,676 -24,110	-69%	-$3.94M	﹤0.01%	713
2025 Q3	$4.87M	Sell	34,786 -975	-3%	-$132K	0.01%	594
2025 Q2	$4.49M	Sell	35,761 -2,351	-6%	-$293K	0.01%	672
2025 Q1	$5.22M	Buy	38,112 +16,443	+76%	+$2.35M	0.01%	626
2024 Q4	$3.31M	Sell	21,669 -2,442	-10%	-$412K	0.01%	762
2024 Q3	$4.67M	Sell	24,111 -10,470	-30%	-$2.19M	0.01%	642
2024 Q2	$8.02M	Buy	34,581 +7,505	+28%	+$1.63M	0.01%	509
2024 Q1	$5.84M	Sell	27,076 -57,387	-68%	-$13.4M	0.01%	582
2023 Q4	$21.9M	Sell	84,463 -130,009	-61%	-$31.9M	0.04%	288
2023 Q3	$55.1M	Sell	214,472 -120,836	-36%	-$32.3M	0.12%	158
2023 Q2	$95.5M	Buy	335,308 +6,915	+2%	+$2.06M	0.19%	102
2023 Q1	$91.3M	Buy	328,393 +98,583	+43%	+$27.3M	0.2%	103
2022 Q4	$63.6M	Buy	229,810 +157,068	+216%	+$44.4M	0.14%	142
2022 Q3	$19.4M	Buy	72,742 +40,076	+123%	+$8.51M	0.05%	277
2022 Q2	$6.66M	Sell	32,666 -37,400	-53%	-$7.65M	0.02%	460
2022 Q1	$14.8M	Buy	70,066 +10,415	+17%	+$2.26M	0.03%	343
2021 Q4	$14.3M	Sell	59,651 -59,105	-50%	-$15.2M	0.03%	394
2021 Q3	$33.6M	Sell	118,756 -24,794	-17%	-$8.13M	0.07%	223
2021 Q2	$49.7M	Buy	143,550 +27,117	+23%	+$8.21M	0.1%	178
2021 Q1	$32.6M	Sell	116,433 -25,768	-18%	-$6.95M	0.07%	235
2020 Q4	$34.8M	Sell	142,201 -1,008	-0.7%	-$260K	0.08%	219
2020 Q3	$40.6M	Sell	143,209 -43,424	-23%	-$12.1M	0.1%	168
2020 Q2	$49.9M	Sell	186,633 -92,105	-33%	-$27.7M	0.14%	132
2020 Q1	$88.2M	Buy	278,738 +2,436	+0.9%	+$739K	0.3%	78
2019 Q4	$82M	Buy	+276,302	New	+$76.7M	0.22%	89

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's BIIB Position: Q2 2026 in Review

Ensign Peak Advisors increased its Biogen (BIIB) stake by 11% in Q2 2026, buying an estimated $697K and bringing the position to 37,354 shares worth $8.07M. The position accounts for 0.01% of the portfolio, ranked #476.

Ensign Peak Advisors first reported a position in BIIB in Q4 2019 and has held it in 27 quarters since. The position peaked at $95.5M in Q2 2023. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Ensign Peak Advisors held 37,354 shares of Biogen worth $8.07M as of Q2 2026.
Ensign Peak Advisors bought 3,644 Biogen shares in Q2 2026, an estimated $697K.
Biogen made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #476 holding.
Ensign Peak Advisors first reported a position in Biogen in Q4 2019 and has held it in 27 quarters since.
Ensign Peak Advisors's Biogen position peaked at $95.5M in Q2 2023.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.